Please assess the completion status of the following clinical trial:

Trial Title: Maribavir for Prevention of CMV After Stem Cell Transplants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Allogeneic stem cell transplant recipient~* Recipient CMV seropositive~* Have transplant engraftment~* Able to swallow tablets~Exclusion Criteria:~* CMV organ disease~* HIV infection~* Use of other anti-CMV therapy post-transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Maribavir (100 mg twice daily) (Type: EXPERIMENTAL): None
- Maribavir (400 mg twice daily) (Type: EXPERIMENTAL): None
- Maribavir (400 mg once daily) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).